US2017143726A1PendingUtilityA1
Adenosine receptor agonists and antagonists to modulate t cell responses
Est. expirySep 7, 2027(~1.1 yrs left)· nominal 20-yr term from priority
A61P 31/00A61K 45/06A61K 38/177A61P 37/00A61K 39/39558A61K 2039/505A61P 37/04A61K 31/53A61P 37/06C07K 16/40A61P 35/00
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described are uses of A 2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A 2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.
Claims
exact text as granted — not AI-modified1 . A method of enhancing an immune response in a host, comprising administering to the host an A 2a receptor antagonist in combination or alternation with a checkpoint inhibitor.
2 . The method of claim 1 , wherein the checkpoint inhibitor blocks the action of PD-1 or Lag-3.
3 . The method of claim 1 , wherein the checkpoint inhibitor is B7-H4 or a fragment thereof.Join the waitlist — get patent alerts
Track US2017143726A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.